Unmet Need Mucosal and Uveal Melanoma
|
|
- Barry Wells
- 6 years ago
- Views:
Transcription
1 Unmet Need Mucosal and Uveal Melanoma Matteo Carlino Crown Princess Mary Cancer Centre Westmead and Blacktown Hospitals Melanoma Institute Australia The University of Sydney.
2 Cutaneous Overall Survival Metastatic Melanoma ^ 1-year OS Phase 3 Studies 25 35% 46% 47% 56% 70% 71% 71% Pembro b 74% Dab + Tram c 75% Vem + Cobi 73% Nivo+Ipi (Ph II) % 24% 29% Ipi 45% Dab 58% Nivo a 53% Dab + Tram c 48% Vem + Cobi 2-year OS 64% Nivo + Ipi (Ph II) 55% Pembro 3-year OS 22% Ipi 42% Nivo (Ph I) 44% Dab + Tram 40/45% Pembro (Ph I) 5-year OS 18% Ipi 34% Nivo (Ph I) Slide Courtesy Georgina V Long a BRAF wt only; b Pooled pembrolizumab Q2W and Q3W 10mg/kg; c Pooled Dab + Tram data; Cobi=cobimetinib; Dab=dabrafenib; Ipi=ipilimumab; Nivo=nivolumab; Pembro=pembrolizumab; Tram=trametinib; Vem=vemurafenib.
3 Mucosal Melanoma Melanomas arising from the Oral/nasal cavity Genitourinary tract Anorectum Pathogenesis not linked to Sun exposure 1 Account for 3% of all melanoma cases in Caucasians 1 20% in Asian populations 2 More likely to present at a later stage 3 More likely node +ve worse survival than cutaneous melanoma 1: Postow et.al Curr Oncol Rep (2012) 2: Chi et.al BMC Cancer (2011) 3: Chang et.al Cancer (1998) 3
4 Melanoma Genetics Lower rate of BRAF mutations < 10% 1 C-kit mutations more commonly seen 10-20% of cases 2 1: Curtin et.al NEJM (2005) 2: Lyle &Long JCO (2013) 3: Carlino et.al Oncosicence (2014)
5 Mucosal Genetics Thanks to Graham Mann and the Australian Melanoma Genome Project (under review 2016)
6 Treatment strategies Immunotherapy Targeted therapy Chemo
7 Immunotherapy
8 Overview We conducted a pooled analysis of data from patients with metastatic mucosal melanoma who had received NIVO monotherapy (3 mg/kg), NIVO (1 mg/kg) plus IPI (3 mg/kg), or IPI monotherapy (3 mg/kg) in one of six trials: Phase I: CA and CA Phase II: CheckMate 069 Phase III: CheckMate 037, CheckMate 066, and CheckMate 067 NIVO Monotherapy NIVO+IPI IPI Monotherapy Studies 003/037/038/066/ / /069 Total patients, N Mucosal mel, n (%) 86 (10%) 35 (9%) 36 (10%) Cutaneous mel, n (%) 665 (75%) 326 (80%) 269 (75%) Acral/Ocular/Other 138 (15%) 46 (11%) 52 (15%) 8
9 Baseline Patient Characteristics NIVO (N=86) Mucosal NIVO+IPI (N=35) IPI (N=36) Cutaneous NIVO (N=665) Age, years Median (range) 61 (22 89) 65 (35 86) 61 (31 80) 60 (18 90) Age category, No. (%) <65 years 49 (57) 17 (49) 24 (67) 412 (62) 65 and <75 years 23 (27) 8 (23) 9 (25) 167 (25) 75 years 14 (16) 10 (29) 3 (8) 86 (13) Sex, No. (%) Female 44 (51) 19 (54) 19 (53) 233 (35) ECOG performance status, No. (%) 1 27 (31) 10 (29) 11 (31) 209 (31) M stage, No. (%)* M1c 57 (66) 22 (63) 19 (53) 409 (62) LDH, No. (%) >ULN 41 (48) 17 (49) 16 (44) 253 (38) >2x ULN 15 (17) 7 (20) 4 (11) 76 (11) BRAF status, No. (%) Mutant 4 (5) 2 (6) 4 (11) 151 (23) PD-L1 status, No. (%) ** Positive ( 5%) 15 (17) 10 (29) 7 (19) 228 (34) LDH, lactate dehydrogenase; ULN, upper limit of normal. *Based on cutaneous melanoma criteria. **PD-L1 positivity was defined as 5% of tumor cells exhibiting cell-surface PD-L1 staining of any intensity in a section containing at least 100 evaluable tumor cells. 9
10 Response to Treatment ORR, % (95% CI) * Mucosal (N=86) 23.3 ( ) NIVO NIVO+IPI IPI Cutaneous (N=665) 40.9 ( ) Mucosal (N=35) 37.1 ( ) Cutaneous (N=326) 60.4 ( ) Mucosal (N=36) 8.3 ( ) Cutaneous (N=269) 21.2 ( ) P value vs IPI < < Best overall response, n (%) Complete response 5 (5.8) 46 (6.9) 1 (2.9) 44 (13.5) 0 7 (2.6) Partial response 15 (17.4) 226 (34.0) 12 (34.3) 153 (46.9) 3 (8.3) 50 (18.6) Stable disease 19 (22.1) 112 (16.8) 7 (20.0) 41 (12.6) 3 (8.3) 67 (24.9) Progressive disease 40 (46.5) 245 (36.8) 11 (31.4) 66 (20.2) 27 (75.0) 120 (44.6) Duration of response (mos) Median (95% CI) NR 22.0 (22.0 NR) NR (7.6 NR) NR (13.1 NR) 2.4 ( ) NR (8.8 NR) CI, confidence interval; NR, not reached; ORR, objective response rate. *By RECIST v1.1 in all studies except CA in which RECIST v1.0 was used. 10
11 Tumor Burden Change Mucosal Melanoma 150 NIVO+IPI (N=28) Change from baseline in target lesions (%) Median change: -34.2% 30% reduction in tumor burden by RECIST v Patients 150 NIVO (N=75) 150 IPI (N=32) Change from baseline in target lesions (%) Median change: -1.4% Change from baseline in target lesions (%) Median change: +28.6% -100 Patients -100 Patients 11
12 PFS Mucosal Melanoma Probability of Progression-Free Survival NIVO 0.2 NIVO+IPI 0.1 IPI Number of Patients at Risk Months 12 NIVO (N=86) 15 NIVO+IPI (N=35) 18 IPI (N=36) Median, mos (95% CI) 3.0 ( ) 5.9 (2.8 NR) 2.7 ( ) HR (95% CI) vs IPI 0.61 ( ) 0.42 ( ) -- P value vs IPI* Median follow-up, mos (range) 6.2 ( ) 8.1 ( ) 8.6 ( ) *Unstratified log-rank test. NIVO NIVO+IPI IPI
13 Targeting mutant Kit Multiple Ph2 studies Imatinib, Nilotinib, Sunitinib Studies often included pts with Kit amplification (no responses) RR upto 50% (in those with Kit mutations) No RCT Nilotinib study closed because of slow accrual.
14 Targeting mutant Kit Responses usually transient 1: Hodi et.al JCO(2013)
15 Adjuvant Chemotherapy Randomized Ph II study Observation vs IFN vs temozolomide +Cisplatin Single centre 189 pts stage II and III Multicentre study ongoing 1: Lian et.al CCR(2014)
16 Conclusions: Mucosal Melanoma Immunotherapy less active than in cutaneous melanoma? Indication for Ipi/anti-PD1 over anti-pd1 Consider Kit inhibition for palliative benefit after immunotherapy failure Adjuvant data awaited Chemo Excluded from EORTC adj study
17 Uveal Melanoma <3% of melanoma Arising from the choroid, iris or ciliary body Upto 50% of pts develop metastatic disease 1 Predilection for liver metastasis 1: Kujala et.al IOVS(2003) Chattopadhyay C et al. Cancer 2016
18 Uveal Genetics BRAF/NRAS mutations not seen GNAQ/GNA11 mutations seen>90% cases 1 BAP 1 mutations and Ch 3 monosomy associated with metastatic risk 2 1: Moore et.al Nat Genetics (2016) 2: Carvajal et.al BJ Opthal (2016)
19 Liver targeted treatment Numerous case series Surgery SIR speres RCT of hepatic intraarterial fotemustine vs IV Improvement in RR/PFS 10.5 vs 2.4% No improvement in OS 1: Leyvraz et.al Annals Onc (2014)
20 Uveal-Immunotherapy
21 Baseline characteristics Characteristic Total (N=56) Characteristic Total (N=56) Age at PD-1 start, median yrs (range) 62.4 ( ) Male n (%) 32 (57.1) ECOG PS n (%) (44.6) 22 (39.3) LDH > ULN n (%) 40 (71.4) Metastatic site n (%) Liver Lung Bone Lymph nodes CNS 50 (89.3) 23 (41.1) 14 (25) 11 (19.6) 7 (12.5) # lines of prior systemic therapy n (%) (14.3) 28 (50) 17 (30.4) 3 (5.4) Prior immunotherapy n (%) 36 (64) Prior liver-directed therapy n (%) Bland/chemo/immuno/ radioembolization External beam RT Radiofrequency ablation 13 (23.2) 2 (3.6) 1 (1.8) Presented by: Katy K. Tsai, MD
22 Treatment responses (RECIST v1.1) Best overall response n (%) N=56 Complete response 0 Partial response 2 (3.6) Stable disease >= 6 months 5 (8.9)* Progressive disease 48 (85.7) * 1 patient lost to follow-up with stable disease at 5 months Presented by: Katy K. Tsai, MD
23 Best overall response Change in sum of lesion diameters (RECIST v1.1) 30% Response in liver (41.7% reduction in sum of tumor diameters) on pembrolizumab Presented by: Katy K. Tsai, MD
24 Survival estimates Progression-free survival, % PFS Median (95% CI): 2.6 months ( ) Overall survival, % OS Median (95% CI): 7.7 months ( ) Months Months Presented by: Katy K. Tsai, MD
25 Is Uveal melanoma an immune target? Low mutation burden of UM 1 Predominance of CD4+ve T cells 2 1: Furney SJ et al. Cancer Discov : Rothermal et al. CCR 2016
26 Targeted therapy Uveal melanoma a better targeted therapy candidate than cutaneous melanoma? 1: Carvajal et.al BJO (2016)
27 Targeted therapy-mek inhibitors Promising PhII data with Selumetinib 1: Carvajal et.al ASCO (2016)
28 Targeted therapy-mek inhibitors 1: Carvajal et.al ASCO (2016)
29 Preclinical activity of selumetinib + TMZ Selumetinib potentiated the effects of TMZ in a human colorectal cancer tumor xenograft 1 TMZ has the same active metabolite as DTIC 2 Mean tumor volume (cm 3 ) ± SEM Control Sel 25 mg/kg qd TMZ 6.25 mg/kg qd Sel + TMZ TGI vs control at Day 30 52%* 89%* 103%* Days post selection TMZ-dosing period Sel-dosing period Adapted from 1 *p< DTIC, dacarbazine; PFS, progression-free survival; qd, once daily; Sel, selumetinib; SEM, standard error of the mean; TGI, tumor growth inhibition; TMZ, temozolomide 1. Holt et al. Br J Cancer 2012;106: ; 2. Tsang et al. Cancer Chemother Pharmacol 1991;27:
30 SUMIT: a Phase III, randomized, placebo-controlled, double-blind trial (NCT ) Patients with mum, with no prior systemic therapy Randomized 3:1, stratified by the presence/absence of liver metastases Selumetinib 75 mg bid PO + DTIC 1000 mg/m 2 IV on Day 1 of every 21-day cycle Pbo bid PO + DTIC 1000 mg/m 2 IV on Day 1 of every 21-day cycle Administered until objective disease progression (BICR), intolerable toxicity, or another discontinuation criteria; scanning schedule q6wk Optional open-label treatment: selumetinib +/- DTIC (data not shown) Primary endpoint PFS by central review (RECIST 1.1) Secondary endpoints include ORR, OS, DoR, safety and tolerability Exploratory endpoint MEK pathway mutations in GNAQ/GNA11 Key inclusion criteria mum (histologically or cytologically confirmed) 1 lesion measurable at baseline ECOG PS 0 1 Life expectancy >12 weeks Key exclusion criteria Previous systemic anticancer therapy (may have prior surgery, or intra-hepatic or non-systemic therapy) Protocol amended to ensure all randomized patients had the opportunity to complete 14-week minimum follow-up (two post-baseline tumor assessments) BICR, blinded independent central review; bid, twice daily; DoR, duration of response; DTIC, dacarbazine; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenously; mum, metastatic uveal melanoma; ORR, objective response rate; OS, overall survival; Pbo, placebo; PFS, progression-free survival; Pbo, placebo; PO, orally; q6wk, every 6 weeks; RECIST 1.1, Response Evaluation Criteria In Solid Tumors version 1.1
31 Progression-free survival (primary endpoint) Median PFS by central review was not statistically significantly improved with Sel + DTIC compared with Pbo + DTIC There was a numerical improvement in median PFS with Sel + DTIC compared with Pbo + DTIC by site-based review Probability of progression-free survival Central review (primary analysis) HR 0.78 (95% CI 0.48, 1.27) 2-sided p= Sel + DTIC Pbo + DTIC Probability of progression-free survival Site-based review HR 0.49 (95% CI 0.28, 0.84) 2-sided p= Sel + DTIC Pbo + DTIC Patients at risk: Time from randomization (months) Time from randomization (months) Sel + DTIC Pbo + DTIC Sel + DTIC (n=97) Pbo + DTIC (n=32) Events, n (%) 82 (85) 24 (75) Median, mo Progression free at 3/6 mo 38%/10% 26%/18% Sel + DTIC (n=97) Pbo + DTIC (n=32) Events, n (%) 77 (79) 26 (81) Median, mo Progression free at 3/6 mo 56%/16% 26%/14% Population: full analysis set, data cut-off May 15, Analysis performed using stratified log-rank test with factors for treatment and liver metastases; crosses denote censored data CI, confidence interval; DTIC, dacarbazine; HR, hazard ratio; mo, months; Pbo, placebo; PFS, progression-free survival; Sel, selumetinib
32 Best change in tumor size (%) Best tumor response by central review* GNA11 positive Population: full analysis set, data cut-off May 15, 2015 *Assessed by blinded independent central review using Response Evaluation Criteria In Solid Tumors version 1.1 DTIC, dacarbazine; Pbo, placebo Selumetinib + DTIC Partial response recorded for three patients GNAQ positive Pbo + DTIC No responses recorded GNAQ/GNA11 negative Unknow n Missing
33 Targeted therapy-pkc inhibitors Preclinical models showing PKC inhibitors active in uveal melanoma 1 Synergy with MEKi 2 1: Piperno-Neumannet.al ASCO (2014) 2: Chen et.al Oncogene (2013)
34 AEB071-PKC inhibitor 1: Piperno-Neumannet.al ASCO (2014)
35 Conclusions: Uveal Melanoma No current standard of care Current immunotherapy minimally active Novel strategies in early phase trials Liver directed therapy can be considered in selected cases.
36 Moving Forward More translational science More Trials
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationBreakthrough and Landscape of Acral and Mucosal Melanomas. Jun Guo. M.D., Ph.D Peking University Cancer Hospital & Institute
Breakthrough and Landscape of Acral and Mucosal Melanomas Jun Guo. M.D., Ph.D Peking University Cancer Hospital & Institute Current status of advanced melanoma Current status of advanced MM Targeted therapy
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationMELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone
MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationUpdate on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationEfficacy of anti-pd-1 therapy in patients with melanoma brain metastases
Efficacy of anti-pd-1 therapy in patients with melanoma brain metastases John J. Park 1, Sagun Parakh 2,3,4, Shehara Mendis 5, Rajat Rai 6, Wen Xu 7, Serigne Lo 6, Martin Drummond 6, Catherine Rowe 7,
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationpresentation session & clinical Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania
Melanoma: highlights from the oral presentation session & clinical science symposium at ASCO 2009 Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania Abstracts to be discussed
More informationRare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham
Rare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham Classifying melanoma Melanoma (site of origin, thickness,
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationÍndice. Melanoma Cáncer de Pulmón Otros tumores
Índice Melanoma Cáncer de Pulmón Otros tumores Carcinoma de Vejiga Carcinoma de Células Renales Carcinoma de Cabeza y Cuello Carcinomas del tubo digestivo Cáncer de Mama MELANOMA CIRUGÍA CIRUGÍA + INFa
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationUniversity of California Los Angeles, Los Angeles, CA; 2. Department of Dermatology, University of Kiel, Kiel, Germany;
Final Efficacy Results of A3671009, a Phase III Study of Tremelimumab vs Chemotherapy (Dacarbazine or Temozolomide) in First-line Patients With Unresectable Melanoma Antoni Ribas, 1 Axel Hauschild, 2 Richard
More informationA View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationAppendices. Appendix A Search terms
Appendices Appendix A Search terms Database Search terms Medline 1. Ipilimumab; 2. MDX-010; 3. MDX-101; 4. Yervoy; 5. BMS-734016; 6. Nivolumab; 7. ONO-4538; 8. BMS-936558; 9. MDX-1106; 10. Opdivo; 11.
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationOverall Survival (OS) Analysis From an Expanded Access Program (EAP) of Nivolumab (NIVO) in Combination with Ipilimumab (IPI) in Patients with Advanced Melanoma (MEL) David Hogg, Paul B. Chapman, 2 Mario
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationNormal RAS-RAF (MAPK) pathway signaling
BRAF-Mutations in Melanomas L. Mazzucchelli Istituto Cantonale di Patologia, Locarno 77. Annual Meeting Swiss Society of Pathology, Lucerne 2011 Sponsored by Roche Pharma Switzerland Melanoma has increased
More informationSupplementary Online Content
Supplementary Online Content Jänne PA, van den Heuvel MM, Barlesi F, et al. Effect of selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRASmutant
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationA Case Study: Ipilimumab in Pre-treated Metastatic Melanoma
A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma Tai-Tsang Chen, PhD Global Biometric Sciences, Bristol-Myers Squibb EFSPI Statistical Meeting on Evidence Synthesis Brussels, Belgium November
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationImmunotherapy & radiotherapy
Immunotherapy & radiotherapy Eric Deutsch MD PhD Gustave Roussy Cancer Campus Image courtesy of Gustave Roussy Institute Disclosure & Disclaimer An honorarium is provided by Accuray for this presentation
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More information